Table 1 Clinical and demographic data of the study samples
From: A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
Study arm | Totals | ||
|---|---|---|---|
PharmG+ (N = 123) | PharmG− (N = 167) | Total (N = 290) | |
Gender | |||
Male | 63 (51.2%) | 94 (56.3%) | 157 (54.1%) |
Female | 60 (48.8%) | 73 (43.7%) | 133 (45.9%) |
Age | |||
Mean (SD) (years) | 46.11 ± 13.7 | 48.68 ± 13.46 | |
Diagnosis | |||
Schizophrenia | 86% | 69% | 76% |
Schizoaffective | 5% | 4% | 4% |
Delusional disorder | 9% | 27% | 20% |
Treatment | |||
Drug | |||
Clozapine | 43 (35%) | 88 (52.7%) | 131 (45.2%) |
Risperidone | 16 (13%) | 20 (12%) | 36 (12.4%) |
Olanzapine | 25 (20.3%) | 14 (8.4%) | 39 (13.4%) |
Paliperidone | 16 (13%) | 22 (13%) | 38 (13.1%) |
Aripiprazole | 7 (5.7%) | 13 (7.8%) | 20 (6.9%) |
Quetiapine | 11 (8.9%) | 5 (3%) | 16 (5.5%) |
Ziprasidone | 1 (0.8%) | 2 (1.2%) | 3 (1%) |
Trifluoperazine | 1 (0.8%) | 1 (0.6%) | 2 (0.7%) |
Haloperidol | 1 (0.8%) | 1 (0.6%) | 2 (0.7%) |
Asenapine | 1 (0.8%) | 1 (0.6%) | 2 (0.7%) |
Pimozide | 1 (0.8%) | 0 | 1 (0.3%) |
Dose (olanzapine equivalent) | |||
Average dose (SD) | 11.57 ± 7.28 | 10.65 ± 5.70 | |
PANSS basal scores | |||
Mean (SD) | 99.23 ± 18.08 | 91.55 ± 17.55 | |
UKU basal scores | |||
Mean (SD) | 9.15 ± 5.98 | 6.83 ± 5.40 | |
